Bulk Pharmaceutical API Sources for apixaban

Bulk Pharmaceutical API Sources for apixaban

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS005146204
BioChemPartner		BCPP000396
AbMole Bioscience		1649
BioChemPartner		BCP9000310

Apixaban API Sources: Global Supply Chain Analysis

Last updated: February 19, 2026

This report details current and emerging bulk active pharmaceutical ingredient (API) sources for apixaban, a direct factor Xa inhibitor used for stroke prevention in atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. The analysis focuses on geographical distribution, key manufacturers, manufacturing capacity, and patent landscapes impacting supply.

What are the primary geographical sources for Apixaban API?

The global supply of apixaban API is concentrated in Asia, with China and India as the dominant manufacturing hubs. These regions offer cost advantages and established pharmaceutical manufacturing infrastructure.

• China: Holds a significant share of global apixaban API production. Numerous domestic chemical and pharmaceutical companies are engaged in its synthesis.
• India: A major supplier, with a well-developed generic API industry. Indian manufacturers compete on cost-effectiveness and adherence to international quality standards.
• Europe: While not a primary bulk API manufacturing region for apixaban, some European companies are involved in intermediate synthesis or specialized API production.
• North America: API manufacturing for apixaban is limited. Companies here may focus on advanced intermediates or final drug product formulation rather than bulk API.

Who are the key Apixaban API manufacturers?

Several companies, both branded and generic, are involved in the production of apixaban API. The landscape includes original innovator suppliers and a growing number of generic manufacturers.

• Original Innovator Supplier: Bristol Myers Squibb (BMS) and Pfizer, through their joint venture, are the primary innovators and original manufacturers of Eliquis®, the branded apixaban product. They control the initial API supply.
• Major Generic API Manufacturers:
  • Lupin Limited (India): Has established itself as a significant supplier of apixaban API, catering to the global generic market.
  • Dr. Reddy's Laboratories (India): A prominent Indian pharmaceutical company with API manufacturing capabilities that include apixaban.
  • Sun Pharmaceutical Industries Ltd. (India): Another leading Indian generic manufacturer with the capacity to produce apixaban API.
  • Aurobindo Pharma (India): Known for its extensive API portfolio, Aurobindo is a key player in the apixaban API supply chain.
  • Teva Pharmaceutical Industries Ltd. (Israel): A global generic pharmaceutical giant with API manufacturing operations, including for apixaban.
  • Zydus Lifesciences (formerly Cadila Healthcare) (India): Has capabilities in complex API synthesis, including apixaban.
  • Major Chinese API Manufacturers: Numerous Chinese companies, often operating as contract manufacturing organizations (CMOs) or independent API producers, supply apixaban API. Specific company names are often less publicly disclosed due to B2B transactional nature but include entities within established chemical and pharmaceutical industrial parks.

These generic manufacturers typically supply the API to formulation companies that then produce the finished dosage forms for their respective markets, especially post patent expiry in key regions.

What is the estimated manufacturing capacity for Apixaban API?

Estimating precise global manufacturing capacity for apixaban API is challenging due to proprietary data and the dynamic nature of the market. However, industry analysis suggests:

• Sufficient Capacity for Global Demand: The combined capacity of major Indian and Chinese API manufacturers, along with internal capacity of innovators, is assessed as sufficient to meet current and projected global demand for apixaban.
• Scalability: Existing facilities in India and China are designed for large-scale chemical synthesis and can be scaled to accommodate increasing production volumes driven by generic market entry and growing patient populations.
• Expansion Trends: Manufacturers are likely to invest in expanding capacity in anticipation of patent expiries and increased generic competition, particularly in markets like the United States and Europe.
• Regulatory Compliance: Capacity is often contingent on adherence to Good Manufacturing Practices (GMP) and successful inspections by regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

A general estimation places the aggregated potential global API manufacturing capacity for apixaban in the hundreds of metric tons annually, with a significant portion dedicated to serving the generic market post-exclusivity periods.

What is the patent landscape impacting Apixaban API supply?

The patent landscape is critical for understanding market entry for generic API manufacturers and influences pricing and supply dynamics.

• Core Compound Patents: The primary patents covering the apixaban molecule itself have been subject to expiry in major markets.
  • US Patent 7,354,959: Granted to Bristol-Myers Squibb, covering apixaban. This patent has faced challenges and expirations.
  • European Patent EP1351747B1: Another key patent for the apixaban compound.
• Method of Synthesis Patents: Patents related to specific manufacturing processes for apixaban are also crucial. Generic manufacturers must develop non-infringing synthesis routes.
  • Companies actively work to design alternative synthesis pathways to circumvent existing process patents held by the innovator.
• Formulation Patents: While not directly impacting API supply, patents on specific drug formulations can influence the overall market.
• Patent Expiry and Generic Entry:
  • United States: Key patents began expiring around 2018-2019, leading to the introduction of generic apixaban products. This significantly expanded the market for generic API suppliers.
  • Europe: Patent expiries have varied by country and specific patent, but generic entry has been progressively occurring.
  • Other Markets: Expiry timelines differ globally based on national patent laws and registration processes.

The ongoing litigation and development of novel synthesis routes by generic companies continue to shape the patent-protected environment for apixaban API.

What are the regulatory considerations for Apixaban API sourcing?

Sourcing apixaban API requires strict adherence to a complex web of international and national regulations to ensure product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies such as the FDA, EMA, and national authorities in India and China. This includes robust quality management systems, facility controls, and process validation.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls.
  • US DMFs: Submitted to the FDA.
  • European CEPs (Certificate of Suitability to the Monographs of the European Pharmacopoeia): Granted by the EDQM, demonstrating compliance with European Pharmacopoeia standards.
• Inspections and Audits: API manufacturing sites are subject to routine inspections by regulatory authorities. Pharmaceutical companies also conduct their own audits of API suppliers to ensure compliance and reliability.
• Impurity Profiling and Control: Stringent control over process-related impurities and degradation products is essential. Regulatory guidelines (e.g., ICH Q3A(R2)) define acceptable limits for impurities.
• Supply Chain Security and Traceability: Ensuring the integrity of the API supply chain from raw materials to finished product is paramount. Measures to prevent counterfeiting and ensure traceability are critical.
• Intellectual Property Rights: Generic API manufacturers must navigate and respect existing intellectual property rights, including patents on synthesis routes, to avoid legal challenges.

Compliance with these regulations is a prerequisite for any API supplier aiming to serve regulated markets like the U.S. and Europe.

What are the quality control requirements for Apixaban API?

Quality control for apixaban API is rigorous, involving comprehensive testing to ensure purity, potency, and absence of harmful contaminants.

• Identity Testing: Confirmation of the chemical structure of apixaban using methods like infrared spectroscopy (IR) and nuclear magnetic resonance (NMR).
• Assay/Potency: Quantitative determination of the apixaban content, typically using high-performance liquid chromatography (HPLC) with UV detection. The assay must fall within specified pharmacopoeial limits (e.g., 98.0% to 102.0% on a dried basis).
• Impurity Testing:
  • Related Substances: HPLC methods are used to detect and quantify process-related impurities and degradation products. Limits are set according to ICH guidelines and pharmacopoeial monographs.
  • Residual Solvents: Gas chromatography (GC) is employed to measure residual solvents used in the manufacturing process, ensuring they are below acceptable limits (ICH Q3C).
  • Heavy Metals: Testing for the presence of heavy metals, ensuring compliance with pharmacopoeial standards.
• Physical Properties:
  • Appearance: Visual inspection for color and form.
  • Solubility: Determination of solubility in specified solvents.
  • Particle Size Distribution: Important for formulation and dissolution characteristics, often measured by laser diffraction.
  • Polymorphism: Characterization of crystalline forms, as different polymorphs can affect bioavailability and stability. Techniques include X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC).
• Water Content: Determined by Karl Fischer titration.
• Microbial Limits: Testing for the absence of unacceptable levels of microorganisms.

Adherence to pharmacopoeial standards (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.)) is a baseline requirement, alongside specific customer specifications.

What are the cost drivers for Apixaban API?

The cost of apixaban API is influenced by several interconnected factors.

• Raw Material Costs: The price and availability of key starting materials and intermediate chemicals used in the synthesis of apixaban are significant cost drivers. Fluctuations in global commodity prices and supply chain disruptions for these precursors can impact API cost.
• Manufacturing Complexity and Yield: The multi-step synthesis of apixaban involves complex chemical reactions. The efficiency of these processes, including reaction yields at each stage, directly affects the overall cost. Lower yields necessitate more raw materials and processing time.
• Labor and Energy Costs: Manufacturing in regions with lower labor and energy costs, such as China and India, generally leads to more competitive API pricing compared to Western countries.
• Regulatory Compliance and Quality Control: The substantial investment in maintaining cGMP compliance, conducting rigorous quality control testing, and obtaining regulatory approvals (e.g., DMF submissions, inspections) adds to the API cost.
• Intellectual Property (IP) Landscape: The cost can be higher when operating under licenses or paying royalties related to specific patented synthesis routes. Conversely, developing non-infringing routes can reduce IP-related costs but requires significant R&D investment.
• Economies of Scale: Larger production volumes typically lead to lower per-unit costs due to better utilization of manufacturing capacity and bulk purchasing of raw materials.
• Supply and Demand Dynamics: Market demand, coupled with the number of active API suppliers, influences pricing. Increased competition among generic API manufacturers tends to drive prices down.
• Logistics and Shipping: The cost of transporting API globally, including specialized handling and import/export duties, contributes to the final landed cost.

Key Takeaways

• Apixaban API supply is predominantly sourced from China and India, driven by cost efficiencies and established manufacturing bases.
• Key manufacturers include major generic players like Lupin, Dr. Reddy's, Sun Pharma, Aurobindo, and Teva, alongside numerous Chinese chemical companies.
• Global manufacturing capacity is assessed as sufficient, with potential for expansion to meet growing demand and generic market penetration.
• The patent landscape, particularly the expiry of core compound and method-of-synthesis patents, has opened significant opportunities for generic API suppliers in key regulated markets.
• Regulatory compliance, including cGMP, DMF submissions, and stringent quality control testing, is paramount for API suppliers in the apixaban market.
• API costs are influenced by raw material prices, manufacturing complexity, labor, energy, regulatory overhead, IP considerations, and economies of scale.

Frequently Asked Questions

• Q1: What is the typical shelf-life of bulk apixaban API? The typical shelf-life for apixaban API, when stored under recommended conditions (e.g., in well-closed containers, protected from light and moisture), is generally 2 to 3 years. Manufacturers provide specific expiry dating based on their stability study data.

• Q2: Are there any APIs that are precursors to apixaban that are subject to specific export/import controls? While apixaban itself is not typically controlled as a precursor, the specific chemical intermediates used in its synthesis may be subject to chemical control regulations in certain jurisdictions if they have other illicit uses. Manufacturers must comply with all relevant chemical import/export laws for their specific starting materials and intermediates.

• Q3: How does particle size distribution of apixaban API impact its use in tablet formulation? The particle size distribution of apixaban API is a critical parameter for tablet formulation. It influences flowability of the powder during tablet compression, blend uniformity with excipients, and ultimately the dissolution rate and bioavailability of the finished dosage form. Manufacturers aim for a consistent and optimized particle size range for reliable manufacturing and therapeutic performance.

• Q4: What is the difference between a Certificate of Suitability (CEP) and a Drug Master File (DMF) for apixaban API? A CEP is issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and certifies that an API complies with the requirements of the European Pharmacopoeia monograph. It allows manufacturers to refer to the CEP in their marketing authorization applications within Europe. A DMF is submitted to regulatory agencies like the U.S. FDA and contains detailed, confidential information about the API's manufacturing, quality, and controls. It is referenced by drug product applicants rather than being a standalone approval of the API itself.

• Q5: Can apixaban API be sourced from contract manufacturing organizations (CMOs)? Yes, apixaban API is frequently manufactured by Contract Manufacturing Organizations (CMOs), particularly in China and India. Pharmaceutical companies, including generic drug developers, often outsource API production to CMOs to leverage specialized expertise, reduce capital investment, and achieve cost efficiencies. These CMOs must meet the same stringent regulatory and quality standards as in-house manufacturers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). U.S. Patent 7,354,959. Retrieved from https://patft.uspto.gov/ (Note: Direct patent links are not stable, but this is the general search portal).

[2] European Patent Office. (n.d.). European Patent EP1351747B1. Retrieved from https://worldwide.espacenet.com/ (Note: Direct patent links are not stable, but this is the general search portal).

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline, Impurities: Guideline for Residual Solvents Q3C(R6).

[4] United States Pharmacopeial Convention. (n.d.). Apixaban Monograph. United States Pharmacopeia.

[5] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia. Retrieved from https://www.edqm.eu/